- Open
- 691.11
- High
- 691.18
- Low
- 611.70
- Close
- 640.00
- Change
- -91.00 (-12.82%)
- Volume
- 30,673
| 30 Sept 2026 | 07:00:03 | Total Voting Rights |
| 28 Sept 2026 | 07:00:07 | Half-year Financial Report |
| 3 Sept 2026 | 07:00:01 | Exercise of Warrants and Issue of Equity |
| 11 Aug 2026 | 07:00:03 | Collaboration with Cellin Technologies |
| 16 May 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 20 May 2025 | Annual Report & Financial Statements for the Year Ended 31 December 2024 | |
| 6 May 2025 | Annual Report and Accounts (to 2024-12-31) |
Hemogenyx Pharmaceuticals plc is a biopharmaceutical company focused on developing treatments for blood and autoimmune disorders. The company is engaged in the pre-clinical stage of research, aiming to utilize bone marrow transplantation to create therapies for these conditions. Hemogenyx operates primarily in the healthcare sector, targeting patients with specific blood-related diseases.
| 30 Sept 2026 | 07:00:03 | Total Voting Rights |
| 28 Sept 2026 | 07:00:07 | Half-year Financial Report |
| 3 Sept 2026 | 07:00:01 | Exercise of Warrants and Issue of Equity |
| 11 Aug 2026 | 07:00:03 | Collaboration with Cellin Technologies |
| 16 May 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 20 May 2025 | Annual Report & Financial Statements for the Year Ended 31 December 2024 | |
| 6 May 2025 | Annual Report and Accounts (to 2024-12-31) |
Hemogenyx Pharmaceuticals plc is a biopharmaceutical company focused on developing treatments for blood and autoimmune disorders. The company is engaged in the pre-clinical stage of research, aiming to utilize bone marrow transplantation to create therapies for these conditions. Hemogenyx operates primarily in the healthcare sector, targeting patients with specific blood-related diseases.
| 29 Jul 2026 |
| 07:00:05 |
| Collaboration and Company Update |
| 29 Jul 2026 |
| 07:00:05 |
| Collaboration and Company Update |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £80.54bn | +0.1% | |
| £2.06bn | +0.5% | |
HEMOHemogenyx Pharmaceuticals plc | £44m | -0.3% |
| £44m | +0.8% | |
| £40m | -0.2% | |
| £31m | — |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £80.54bn | +0.1% | |
| £2.06bn | +0.5% | |
HEMOHemogenyx Pharmaceuticals plc | £44m | -0.3% |
| £44m | +0.8% | |
| £40m | -0.2% | |
| £31m | — |
